Personal CFO Solutions LLC Has $239,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Personal CFO Solutions LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,789 shares of the life sciences company’s stock after buying an additional 150 shares during the quarter. Personal CFO Solutions LLC’s holdings in Illumina were worth $239,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. NS Partners Ltd lifted its position in shares of Illumina by 44.4% during the 4th quarter. NS Partners Ltd now owns 53,566 shares of the life sciences company’s stock worth $7,158,000 after buying an additional 16,463 shares during the period. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of Illumina during the fourth quarter worth $601,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the fourth quarter worth $45,000. Edgestream Partners L.P. grew its stake in shares of Illumina by 94.1% during the fourth quarter. Edgestream Partners L.P. now owns 23,705 shares of the life sciences company’s stock worth $3,168,000 after purchasing an additional 11,493 shares during the period. Finally, Prescott Group Capital Management L.L.C. grew its stake in Illumina by 200.0% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 9,000 shares of the life sciences company’s stock valued at $1,203,000 after acquiring an additional 6,000 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of research analyst reports. Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Morgan Stanley dropped their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, Robert W. Baird decreased their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $149.25.

Illumina Stock Down 0.8 %

ILMN opened at $85.97 on Tuesday. The company has a fifty day moving average price of $117.43 and a 200-day moving average price of $131.17. The firm has a market capitalization of $13.62 billion, a P/E ratio of -11.19, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.